Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Using Conversation Maps to Reinforce Self-Care

This study has been completed.
Sponsor:
Collaborator:
American Diabetes Association
Information provided by (Responsible Party):
Joslin Diabetes Center
ClinicalTrials.gov Identifier:
NCT00895986
First received: May 7, 2009
Last updated: October 17, 2012
Last verified: October 2012

May 7, 2009
October 17, 2012
December 2008
March 2012   (final data collection date for primary outcome measure)
Improved frequency of recommended self-care behaviors (Self-Care Inventory-R) [ Time Frame: 3, 6, and 12 months post intervention ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00895986 on ClinicalTrials.gov Archive Site
  • HbA1c [ Time Frame: 3, 6, and 12 months post intervention ] [ Designated as safety issue: No ]
  • Diabetes Quality of Life (scale) [ Time Frame: 3, 6, and 12 months post intervention ] [ Designated as safety issue: No ]
  • Major mediating/moderating variables include Problem Areas in Diabetes, Brief Symptom Inventory, Coping Styles, and Confidence in Diabetes [ Time Frame: 3, 6, and 12 months post intervention ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Using Conversation Maps to Reinforce Self-Care
Achieving and Maintaining Glycemic Control: Using Conversation Maps to Reinforce Self-Care

Many people with type 2 diabetes are not able to keep their blood glucose in good control. Improving blood glucose control and maintaining that improvement is important for diabetes patients because doing so delays the onset and progression of severe complications of diabetes. Although educational programs may be helpful, their effect is not always long-lasting. This project is studying whether the Conversation Maps program (an interactive diabetes education program) reinforces diabetes education and information and thus helps type 2 diabetes patients take better care of their diabetes and blood glucose levels. Half of the patients will attend the Conversation Maps program and half of the patients will attend an educational program about blood pressure and cholesterol. Also, all patients will come in for 4 or 5 appointments to complete surveys and other tests and have their blood drawn. The group of patients who attend the Conversation Maps program will be compared to the group of patients who attend the blood pressure and cholesterol program to see if the educational programs helped diabetes patients to improve their diabetes control and quality of life and to maintain that improvement over time.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Type 2 Diabetes
  • Behavioral: Conversation Maps Diabetes Education
    The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
  • Behavioral: Heart Healthy Living Diabetes Education
    The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
  • Experimental: 1
    Conversation Maps Diabetes Education
    Intervention: Behavioral: Conversation Maps Diabetes Education
  • Experimental: 2
    Heart Healthy Living Diabetes Education
    Intervention: Behavioral: Heart Healthy Living Diabetes Education
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
134
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ages 25-75 years
  • Diagnosis of type 2 diabetes mellitus
  • Two A1c levels ≥7.0 % (above ADA target)
  • 2 years since initial diagnosis. This will provide a minimum of two-years experience with diabetes treatment. Also, excluding those who are newly diagnosed will prevent improvement due to newly prescribed medications from confounding study results.
  • Attended one of Joslin's group education programs or comparable 3-hour (or more) educational programs and/or appointments

Exclusion Criteria:

  • Severe complications of diabetes including renal disease (microalbumin >300 ug/mg), severe peripheral diabetic neuropathy and/or severe peripheral vascular disease, symptomatic severe autonomic neuropathy, that may place participants at risk when increasing activity levels.
  • Proliferative diabetic retinopathy based on dilated eye examination within one year of study entry. Patients whose eye disease is successfully treated will be included.
  • Current or planned pregnancy
  • A1c levels less than 7.0% (normal range 4.0 - 6.0%) and A1c levels greater than 14%.
  • A history of severe, unstable myocardial infarction, congestive heart failure or other severe cardiac disease, or severe hypertension (systolic ≥160 mmHg or diastolic ≥ 90 mmHg) (increased risk when mildly increasing physical activity).
  • A diagnosis of bipolar disorder, schizophrenia, mental retardation, organic mental disorder, and alcohol or drug abuse will be excluded, as well as patients currently undergoing psychiatric treatment. These exclusions are being made to avoid confounds due to concurrent changes in mental status and the effects of ongoing psychiatric treatment.
  • Used Conversation Maps as an educational tool
  • Started a new diabetes medication (pills or insulin) in past three months
Both
25 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00895986
ADA 7-08-CR-62, CHS #08-07
No
Joslin Diabetes Center
Joslin Diabetes Center
American Diabetes Association
Principal Investigator: Katie Weinger, EdD, RN Joslin Diabetes Center
Joslin Diabetes Center
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP